Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus
article
OA: closed
CC0
Abstract
PurposeCyclophosphamide-induced ovarian failure has been reported to be protective against flares of systemic lupus erythematosus (SLE). We studied whether patients with SLE experience a decrease in disease activity after natural menopause.Subjects and methodsWe studied 30 SLE patients with natural menopause who had been observed at least 2 years before and after menopause and who did not receive hormone replacement therapy or danazol. Menopause was defined as the date of the last self-reported menstrual period. Disease activity was assessed retrospectively by medical chart review using standard measures (the SLE disease activity index) during the immediate premenopausal and postmenopausal periods, and 2 (n = 30 patients), 3 (n = 19), and 4 (n = 13) years before and after menopause. We also compared the use of health services and medications.ResultsPatients were studied for a mean (+/- SD) of 6.4 +/- 1.7 years (premenopausal, 3.3 +/- 0.9 years; postmenopausal, 3.2 +/- 0.9 years). During the premenopausal periods, the mean disease activity score was 2.3 +/- 2.3 (range, 0 to 9 on a 0 to 105 scale), compared with 2.3 +/- 2.9 (range, 0 to 12; P = 0.37) after menopause. The maximum disease activity score was somewhat greater in the premenopausal period (7.9 +/- 6.0 [range, 0 to 22] vs. 5.8 +/- 5.1 [range, 0 to 22]; P = 0.04). The incidence rates of flares (0.56 per year vs. 0.43 per year, P = 0.20) and severe flares (0.17 per year vs. 0.12 per year, P = 0.33) were similar in the premenopausal and postmenopausal periods. Differences in disease activity scores (mean and maximum) and the number of visits to a rheumatologist's office were only significant when the fourth year before menopause was compared with the fourth year after menopause.ConclusionsDisease activity is mild during the premenopausal and postmenopausal periods in women with SLE. A modest decrease, especially in the maximum disease activity, is seen after natural menopause.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (45)
- doi:10.1016/0378-5122(91)90251-k via openalex
- doi:10.1093/oxfordjournals.aje.a112673 via openalex
- doi:10.1002/art.1780250603 via openalex
- doi:10.7326/0003-4819-21-6-1022 via openalex
- doi:10.1001/jama.1963.03700110049009 via openalex
- doi:10.1002/1529-0131(199906)42:6<1274::aid-anr26>3.0.co;2-b via openalex
- doi:10.1002/art.1780210413 via openalex
- doi:10.1177/096120339400300104 via openalex
- doi:10.3109/13697139909038088 via openalex
- doi:10.1016/0378-5122(86)90039-3 via openalex
- doi:10.1093/oxfordjournals.aje.a113386 via openalex
- doi:10.1172/jci109390 via openalex
- doi:10.1172/jci108729 via openalex
- doi:10.1002/art.1780350606 via openalex
- doi:10.1210/jcem-42-4-629 via openalex
- W93190295 via openalex
- doi:10.1002/art.1780251101 via openalex
- doi:10.1016/0002-9378(75)90016-2 via openalex
- doi:10.1016/0378-5122(86)90025-3 via openalex
- doi:10.1136/ard.48.6.455 via openalex
- doi:10.1002/art.1780400505 via openalex
- doi:10.1093/ije/14.3.463 via openalex
- doi:10.1016/0378-5122(86)90038-1 via openalex
- doi:10.1007/978-94-011-3896-3_9 via openalex
- doi:10.1093/rheumatology/25.3.300 via openalex
- doi:10.1002/art.1780360623 via openalex
- W2203376376 via openalex
- W2396961843 via openalex
- W2408054339 via openalex
- W2410113204 via openalex
- W2417585296 via openalex
- W6603783100 via openalex
- doi:10.1016/s0140-6736(98)05352-5 via openalex
- doi:10.1093/aje/126.2.319 via openalex
- W6700133316 via openalex
- W6717278142 via openalex
- doi:10.1111/j.1479-8077.2006.00199_10.x via openalex
- doi:10.7326/0003-4819-122-6-199503150-00005 via openalex
- doi:10.1002/art.1780400109 via openalex
- doi:10.1002/art.1780340802 via openalex
- doi:10.1002/art.1780281108 via openalex
- doi:10.1097/00006254-196308000-00009 via openalex
- doi:10.1080/03009749850154357 via openalex
- doi:10.1084/jem.147.6.1568 via openalex
- doi:10.1016/0895-4356(96)89163-3 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:37:04.871248+00:00
- unpaywall
- last seen: 2026-08-22T06:23:50.750314+00:00
License: CC0
· commercial use OK